This study is for people with advanced non-small cell lung cancer (NSCLC) that has a change in the epidermal growth factor receptor (EGFR) gene. The study compares two treatments: sacituzumab tirumotecan and a combination of drugs called pemetrexed and carboplatin. People in the study have cancer that got worse even after taking another type of medicine called EGFR tyrosine kinase inhibitors (TKIs). The main goal is to see if sacituzumab tirumotecan helps people live longer without the cancer growing and improves overall survival compared to the other treatment.

• Participants will be divided into two groups and receive one of the treatments.
• The study lasts as long as the treatment continues to be effective, and participants will stop if certain criteria are met.
• Participants must have a life expectancy of at least 3 months and no serious other health issues.

Before joining, participants must have confirmed advanced NSCLC and be free of major infections or other severe health conditions. It's important to discuss with a doctor to understand the risks and benefits.